Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SGEN |
---|---|---|
09:32 ET | 5055 | 174.6 |
09:34 ET | 4053 | 175.39 |
09:36 ET | 460 | 175.7 |
09:38 ET | 200 | 175.65 |
09:39 ET | 100 | 175.1 |
09:41 ET | 8265 | 174.37 |
09:43 ET | 1500 | 174.6189 |
09:45 ET | 2200 | 174.51 |
09:48 ET | 300 | 174.72 |
09:50 ET | 2300 | 174.51 |
09:52 ET | 300 | 174.89 |
09:54 ET | 300 | 174.75 |
09:56 ET | 1124 | 174.8 |
09:57 ET | 800 | 174.96 |
09:59 ET | 800 | 175.6 |
10:01 ET | 2100 | 174.9 |
10:03 ET | 1200 | 174.89 |
10:06 ET | 200 | 174.93 |
10:08 ET | 424 | 174.61 |
10:10 ET | 6631 | 173.84 |
10:12 ET | 1100 | 174.2 |
10:14 ET | 1000 | 174.21 |
10:15 ET | 2000 | 174.21 |
10:17 ET | 800 | 174.21 |
10:19 ET | 1100 | 174.57 |
10:21 ET | 3400 | 174.21 |
10:24 ET | 700 | 174.23 |
10:26 ET | 300 | 174.3363 |
10:28 ET | 1300 | 174.2 |
10:30 ET | 500 | 174.04 |
10:32 ET | 700 | 174.08 |
10:33 ET | 1274 | 174.21 |
10:35 ET | 470 | 174.36 |
10:37 ET | 600 | 174.46 |
10:39 ET | 2983 | 173.87 |
10:42 ET | 500 | 174 |
10:44 ET | 500 | 174 |
10:46 ET | 1407 | 173.92 |
10:48 ET | 1784 | 173.71 |
10:50 ET | 600 | 173.77 |
10:51 ET | 200 | 173.9477 |
10:53 ET | 3269 | 173.955 |
10:55 ET | 5646 | 173.91 |
10:57 ET | 200 | 173.95 |
11:00 ET | 1205 | 173.5 |
11:02 ET | 3100 | 173.82 |
11:04 ET | 2947 | 173.71 |
11:06 ET | 100 | 173.71 |
11:08 ET | 800 | 173.68 |
11:09 ET | 100 | 173.62 |
11:11 ET | 1580 | 173.6 |
11:13 ET | 1130 | 173.56 |
11:15 ET | 300 | 173.705 |
11:18 ET | 1890 | 173.985 |
11:20 ET | 605 | 173.965 |
11:22 ET | 3400 | 173.91 |
11:26 ET | 100 | 174.07 |
11:27 ET | 200 | 173.96 |
11:29 ET | 880 | 174.14 |
11:31 ET | 2967 | 174.18 |
11:33 ET | 789 | 174.2 |
11:36 ET | 518 | 174.2 |
11:38 ET | 660 | 174.2 |
11:40 ET | 100 | 174.21 |
11:44 ET | 1300 | 174.26 |
11:45 ET | 848 | 174.26 |
11:47 ET | 2300 | 174.52 |
11:51 ET | 500 | 174.71 |
11:54 ET | 1595 | 174.47 |
11:56 ET | 800 | 174.39 |
11:58 ET | 400 | 174.0875 |
12:00 ET | 22186 | 173.49 |
12:02 ET | 4860 | 173.69 |
12:03 ET | 200 | 173.57 |
12:05 ET | 2293 | 173.93 |
12:07 ET | 300 | 174.37 |
12:09 ET | 871 | 174.5 |
12:12 ET | 200 | 174.62 |
12:16 ET | 600 | 174.92 |
12:18 ET | 975 | 175 |
12:20 ET | 300 | 174.645 |
12:21 ET | 300 | 174.88 |
12:23 ET | 100 | 174.88 |
12:25 ET | 2250 | 174.975 |
12:27 ET | 100 | 174.89 |
12:30 ET | 2100 | 175.02 |
12:34 ET | 2350 | 174.88 |
12:36 ET | 100 | 174.77 |
12:38 ET | 100 | 174.9 |
12:39 ET | 1100 | 174.82 |
12:41 ET | 300 | 174.96 |
12:43 ET | 3000 | 175.315 |
12:45 ET | 200 | 175.175 |
12:48 ET | 600 | 175 |
12:50 ET | 300 | 174.96 |
12:52 ET | 100 | 174.965 |
12:54 ET | 500 | 174.91 |
12:56 ET | 600 | 174.92 |
12:59 ET | 928 | 174.84 |
01:01 ET | 1000 | 175.04 |
01:03 ET | 1300 | 175.2 |
01:06 ET | 1500 | 175.22 |
01:08 ET | 100 | 175.195 |
01:12 ET | 100 | 175.155 |
01:14 ET | 500 | 175.08 |
01:15 ET | 158736 | 168.82 |
01:17 ET | 124548 | 169.79 |
01:19 ET | 81303 | 169.785 |
01:21 ET | 78705 | 170.57 |
01:24 ET | 46471 | 169.8299 |
01:26 ET | 46177 | 169.88 |
01:28 ET | 32291 | 170.029 |
01:30 ET | 18712 | 169.82 |
01:32 ET | 19777 | 169.28 |
01:33 ET | 31226 | 169.7 |
01:35 ET | 18649 | 169.935 |
01:37 ET | 11626 | 169.935 |
01:39 ET | 18961 | 169.51 |
01:42 ET | 11789 | 169.25 |
01:44 ET | 125650 | 169 |
01:46 ET | 18457 | 169.595 |
01:48 ET | 7967 | 169.895 |
01:50 ET | 3606 | 169.555 |
01:51 ET | 21605 | 169.66 |
01:53 ET | 48105 | 170 |
01:55 ET | 17317 | 170.065 |
01:57 ET | 5512 | 170.1671 |
02:00 ET | 15185 | 170.3325 |
02:02 ET | 27188 | 171.005 |
02:04 ET | 7870 | 171.585 |
02:06 ET | 20824 | 172.32 |
02:08 ET | 4420 | 171.88 |
02:09 ET | 6246 | 171.695 |
02:11 ET | 4052 | 171.85 |
02:13 ET | 2650 | 172 |
02:15 ET | 10176 | 171.64 |
02:18 ET | 15749 | 171.365 |
02:20 ET | 13713 | 171.58 |
02:22 ET | 4900 | 171.17 |
02:24 ET | 2400 | 171.075 |
02:26 ET | 19920 | 171.01 |
02:27 ET | 3044 | 170.6 |
02:29 ET | 11498 | 170.56 |
02:31 ET | 9466 | 170.49 |
02:33 ET | 11681 | 170.43 |
02:36 ET | 7431 | 170.585 |
02:38 ET | 4313 | 170.615 |
02:40 ET | 8294 | 170.56 |
02:42 ET | 8210 | 170.88 |
02:44 ET | 10127 | 170.98 |
02:45 ET | 4693 | 170.94 |
02:47 ET | 2250 | 171.105 |
02:49 ET | 4400 | 170.86 |
02:51 ET | 4814 | 170.9 |
02:54 ET | 3600 | 170.96 |
02:56 ET | 4950 | 171.38 |
02:58 ET | 5350 | 171.4528 |
03:00 ET | 2300 | 171.25 |
03:02 ET | 1000 | 171.17 |
03:03 ET | 1688 | 171.215 |
03:05 ET | 3690 | 171 |
03:07 ET | 2809 | 171 |
03:09 ET | 400 | 170.88 |
03:12 ET | 9528 | 170.66 |
03:14 ET | 1191 | 170.81 |
03:16 ET | 4316 | 170.5 |
03:18 ET | 6141 | 170.4 |
03:20 ET | 2900 | 170.25 |
03:21 ET | 7250 | 170.33 |
03:23 ET | 4300 | 170.135 |
03:25 ET | 20073 | 170.22 |
03:27 ET | 7789 | 170.25 |
03:30 ET | 10819 | 170.23 |
03:32 ET | 10859 | 170.22 |
03:34 ET | 12816 | 170.2 |
03:36 ET | 4490 | 170.164 |
03:38 ET | 8395 | 170.15 |
03:39 ET | 15156 | 170.31 |
03:41 ET | 15976 | 170.42 |
03:43 ET | 10446 | 170.47 |
03:45 ET | 23657 | 170.4 |
03:48 ET | 21142 | 170.485 |
03:50 ET | 8600 | 170.3 |
03:52 ET | 32131 | 171.05 |
03:54 ET | 39140 | 171.175 |
03:56 ET | 63110 | 170.97 |
03:57 ET | 78184 | 170.75 |
03:59 ET | 314522 | 170.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Seagen Inc | 32.4B | -42.1x | --- |
Alnylam Pharmaceuticals Inc | 27.8B | -28.6x | --- |
Beigene Ltd | 19.2B | -9.5x | --- |
argenx SE | 20.2B | -32.9x | --- |
Biomarin Pharmaceutical Inc | 17.8B | 410.7x | --- |
United Therapeutics Corp | 10.1B | 16.4x | -7.98% |
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.4B |
---|---|
Revenue (TTM) | $1.8B |
Shares Outstanding | 184.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-4.04 |
Book Value | $16.71 |
P/E Ratio | -42.1x |
Price/Sales (TTM) | 18.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -41.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.